| pubmed-article:11920456 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0678222 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C1517927 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:11920456 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:11920456 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11920456 | pubmed:dateCreated | 2002-3-28 | lld:pubmed |
| pubmed-article:11920456 | pubmed:abstractText | The objective of this study was to test the activity and toxicity of epirubicin plus docetaxel as primary chemotherapy for women with large, operable (T2; > 3 cm) or locally advanced (Stage III) breast carcinoma, including patients with inflammatory breast carcinoma. | lld:pubmed |
| pubmed-article:11920456 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11920456 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920456 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11920456 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920456 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920456 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920456 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11920456 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11920456 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11920456 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:PerroneFrance... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:D'AiutoGiusep... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:BottiGerardoG | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:NuzzoFrancesc... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:LaboniaVincen... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:LandiGabriell... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:RossiEmanuela... | lld:pubmed |
| pubmed-article:11920456 | pubmed:author | pubmed-author:MastroAngelo... | lld:pubmed |
| pubmed-article:11920456 | pubmed:copyrightInfo | Copyright 2002 American Cancer Society.DOI 10.1002/cncr.20335 | lld:pubmed |
| pubmed-article:11920456 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11920456 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11920456 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:11920456 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11920456 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11920456 | pubmed:pagination | 895-901 | lld:pubmed |
| pubmed-article:11920456 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:meshHeading | pubmed-meshheading:11920456... | lld:pubmed |
| pubmed-article:11920456 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11920456 | pubmed:articleTitle | Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. | lld:pubmed |
| pubmed-article:11920456 | pubmed:affiliation | Department of Medical Oncology C, National Cancer Institute, Naples, Italy. f.conuzzo@libero.it | lld:pubmed |
| pubmed-article:11920456 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11920456 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11920456 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11920456 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11920456 | lld:pubmed |
